# OnCo record vivace-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/vivace-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "vivace-therapeutics" ;
  schema:name "Vivace Therapeutics"@en ;
  schema:alternateName "Vivace Therapeutics, Inc."@en, "Vivace Therapeutics, Inc"@en ;
  schema:description "A US company developing VT3989, a pill that blocks the Hippo pathway signal some tumours depend on. It is being tested mainly in mesothelioma, a cancer of the lining of the lungs and abdomen, now moving to a Phase 3 trial."@en ;
  schema:url <https://onco.cc/companies/vivace-therapeutics/>, <https://www.vivacetherapeutics.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/vivace-therapeutics-raises-35-million-in-series-d-financing-to-support-clinical-development-of-first-in-class-cancer-drug-targeting-the-hippo-pathway>, <https://clinicaltrials.gov/study/NCT04665206>, <https://clinicaltrials.gov/study/NCT07824986>, <https://www.racap.com/portfolio/vivace-therapeutics> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/pleural-mesothelioma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/vt3989/> ;
  onco:trials <https://onco.cc/trials/nct04665206/> .